Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
about
Burden of Mycobacterium ulcerans disease (Buruli ulcer) and the underreporting ratio in the territory of Songololo, Democratic Republic of CongoDrugs for treating Buruli ulcer (Mycobacterium ulcerans disease)Clinical and Laboratory Diagnosis of Buruli Ulcer Disease: A Systematic ReviewStructure of the cystathionine γ-synthase MetB from Mycobacterium ulceransActivities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in miceSecondary bacterial infections of buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicinRapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infectionAccelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans diseaseGood quality of life in former Buruli ulcer patients with small lesions: long-term follow-up of the BURULICO trialLong term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial.Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients?In-vitro activity of avermectins against Mycobacterium ulceransSelamectin Is the Avermectin with the Best Potential for Buruli Ulcer TreatmentEfficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans DiseaseSterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in MiceKinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans diseaseResponse to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).Household cost of out-patient treatment of Buruli ulcer in Ghana: a case study of Obom in Ga South Municipality.Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic ReviewAll-oral antibiotic treatment for buruli ulcer: a report of four patients.Experimental infection of the pig with Mycobacterium ulcerans: a novel model for studying the pathogenesis of Buruli ulcer disease.Health services for Buruli ulcer control: lessons from a field study in Ghana.Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.Laboratory confirmation of Buruli ulcer disease in Togo, 2007-2010.Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring.Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?Wound care in Buruli ulcer disease in Ghana and Benin.Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue?Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.Effect of a control project on clinical profiles and outcomes in buruli ulcer: a before/after study in Bas-Congo, Democratic Republic of Congo.Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort studyEfficiency of fine-needle aspiration compared with other sampling techniques for laboratory diagnosis of Buruli ulcer disease.Illness meanings and experiences for pre-ulcer and ulcer conditions of Buruli ulcer in the Ga-West and Ga-South Municipalities of Ghana.Contribution of the community health volunteers in the control of Buruli ulcer in Bénin.Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans.Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.Persisting social participation restrictions among former Buruli ulcer patients in Ghana and Benin.
P2860
Q21090118-32694695-7BD4-4059-9072-0A31A43884CAQ24186073-96224D6C-6D7E-4C04-9A09-55BDB3CB310FQ26740428-8E22F0CA-ABC5-4819-8EA8-B04D51CB4CC2Q27673639-C1ED6BB0-7A32-4AB5-A13B-E896CFB53E1DQ28476689-A1EF55E2-D0B1-49D1-8AE6-392A9E6F4AEAQ28487505-73E0C0BD-B77F-441C-98D9-448FC634B3DDQ28537749-46E60F6E-2794-41F2-B5C9-B5E28CB08118Q28538259-8FF40984-E5AC-4221-BBC7-6F4022107FB4Q28540627-EDA23A47-41D5-482B-B4A5-0B66F5FEC9D6Q28540814-97EAD4FE-08D4-48F8-94BF-F4900D4B12F0Q28543227-C75000B9-EED0-4271-9204-607A21507D4EQ28543887-2A0BD59B-243C-40F0-804E-446B2265AD76Q28547238-0D3348D4-E01D-4058-A1A6-047922F8B7DCQ28552524-2A7DCFFE-3B3A-445B-81B4-A09F2294C76CQ28552736-619162B3-B344-490E-A55A-D07690E6A025Q33613484-C187CDF0-A986-40CC-8E49-5FDB09E0D522Q33631299-5BE7E3C6-EA5B-4280-A95D-DE3261C14441Q33642236-24559ADC-335D-4D50-9242-CD5ABC8A5289Q33658786-27A2DF60-24B5-47C5-8622-9BC3B9B53577Q33769921-733C8100-6929-485E-8E92-549F234AE6C0Q33881961-82F9B4B0-D3CA-41E9-8B66-235EA90FC4B0Q33945445-09E43FC8-BC5B-44B9-A765-5DCD06EA5466Q33962755-9F48DD7B-E384-4ECD-86A0-7B67F9F97030Q33980134-D67D9AC1-92E9-4526-A721-AD22409ABF99Q33980141-4EF6E4C8-2EF7-439B-AAB3-E7A4CBC91842Q33988898-914DC25D-2939-4FBC-92CF-D5C8BCABFB38Q34015935-85DD0D18-627E-493F-952A-871E8653A77CQ34043539-8966DB4E-BFF3-4A79-B493-03DD9B947BD8Q34108761-B97FF249-D627-40A8-B80F-8705DB8F5812Q34108789-17C1250B-AA66-4AB0-8123-EA9C68FDCC11Q34117955-474A8DD7-85A0-435B-AC42-AE579F2239A9Q34137837-F9FFE84C-B68B-477F-B8DE-255C5F7CA7FAQ34190336-60427612-D887-4DB0-8B76-391B32371B72Q34218700-7B7F93B1-E09D-43BC-910F-66EA6C1720D2Q34281971-9F1D7BBA-E2FA-4062-B355-24F410F9E371Q34431496-61E216E2-B5AD-44A5-9DCA-A8B5A7E967E4Q34483614-7B1D3804-B26E-4785-B707-263C28107978Q34484489-6D0C304A-97DE-4A00-B1B7-CB499D9C6E3EQ34500901-1E3DF110-8369-4263-BA5F-18723ABDB04CQ34505664-5D0537E0-CB6E-4D47-A56E-5645FC4DBA59
P2860
Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Antimicrobial treatment for ea ...... a randomised controlled trial.
@en
Antimicrobial treatment for ea ...... a randomised controlled trial.
@nl
type
label
Antimicrobial treatment for ea ...... a randomised controlled trial.
@en
Antimicrobial treatment for ea ...... a randomised controlled trial.
@nl
prefLabel
Antimicrobial treatment for ea ...... a randomised controlled trial.
@en
Antimicrobial treatment for ea ...... a randomised controlled trial.
@nl
P2093
P1433
P1476
Antimicrobial treatment for ea ...... a randomised controlled trial
@en
P2093
Edwin O Ampadu
Jan P Schouten
K Mohammed Abass
Nana Yaa Awua-Boateng
Ohene Adjei
Peter C Awuah
Vera Siegmund
Willemien A Nienhuis
William A Thompson
Wilson Tuah
P304
P356
10.1016/S0140-6736(09)61962-0
P407
P577
2010-02-03T00:00:00Z